Experimental Antibiotic Shows Promise in Fight Against MRSA

This article originally appeared here.
Share this content:
Experimental Antibiotic Shows Promise in Fight Against MRSA
Experimental Antibiotic Shows Promise in Fight Against MRSA

THURSDAY, June 16, 2016 (HealthDay News) -- An experimental antibiotic has shown promise against methicillin-resistant Staphylococcus aureus (MRSA) in animals, according to a study published in the July issue of Antimicrobial Agents and Chemotherapy.

A combination of the new antibiotic TXA709 and the antibiotic cefdinir successfully treated animals infected with MRSA. The results are "important because even though TXA709 is effective on its own in treating MRSA, combining it with cefdinir makes it even more efficacious, while also significantly reducing the potential for the MRSA bacteria to become resistant in the future," researcher Daniel Pilch, Ph.D., an associate professor of pharmacology at the Rutgers University Robert Wood Johnson Medical School in Piscataway, N.J., said in a university news release.

"What is also good about this experimental treatment is that both drugs can be taken orally, which means they can be administered on an outpatient basis. All but two of the current antibiotics being used clinically to treat MRSA need to be administered intravenously," Pilch said.

Pilch and others at Rutgers University developed the experimental antibiotic. Phase 1 clinical trials to test the safety and effectiveness of TXA709 in humans are expected to begin next spring.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »